ITCI (Intra-Cellular Therapies) Debt-to-Equity : 0.02 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Intra-Cellular Therapies Debt-to-Equity?

Intra-Cellular Therapies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $4.2 Mil. Intra-Cellular Therapies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $12.7 Mil. Intra-Cellular Therapies's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $1,148.5 Mil. Intra-Cellular Therapies's debt to equity for the quarter that ended in Dec. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Intra-Cellular Therapies's Debt-to-Equity or its related term are showing as below:

ITCI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.12
Current: 0.02

During the past 13 years, the highest Debt-to-Equity Ratio of Intra-Cellular Therapies was 0.12. The lowest was 0.02. And the median was 0.04.

ITCI's Debt-to-Equity is ranked better than
92.72% of 824 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs ITCI: 0.02

Intra-Cellular Therapies Debt-to-Equity Historical Data

The historical data trend for Intra-Cellular Therapies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Debt-to-Equity Chart

Intra-Cellular Therapies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.06

0.03

0.02

Intra-Cellular Therapies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.03	0.02	0.02	0.02

Competitive Comparison of Intra-Cellular Therapies's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intra-Cellular Therapies's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Intra-Cellular Therapies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Intra-Cellular Therapies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.233	+	12.748)	/	1148.46
	=	0.01

Intra-Cellular Therapies's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.233	+	12.748)	/	1148.46
	=	0.01

Intra-Cellular Therapies (NAS:ITCI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Intra-Cellular Therapies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ITCI:Mexico 23I:Germany I2TC34:Brazil

Address

135 Route 202/206, Suite 6, Bedminster, NJ, USA, 07921

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Executives

Sharon Mates	director, officer: Chairman, President & CEO	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead	officer: SVP and General Counsel	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Mark Neumann	officer: EVP, Chief Commercial Officer	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs	director	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Suresh K. Durgam	officer: Chief Medical Officer	C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline	officer: VP of Finance, CFO & Secretary	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas	director	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Christopher D Alafi	director, 10 percent owner	P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner	director	THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin	officer: EVP and Chief Medical Officer	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover	officer: VP, Clinical Development	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis	officer: SVP, Chief Scientific Officer	3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi	10 percent owner	1311 ORLEANS DRIVE, SUNNYVALE CA 94089